))
Episode 57: Rob Etherington- CEO and President at Clene Nanomedicine
Manage episode 406075324 series 3526490
Innhold levert av Vial. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Vial eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Imagine unlocking the secrets to revitalizing the brain's energy centers and turning the tide on neurodegenerative diseases. In this episode, Rob introduces us to CNM-Au8, an oral nanotherapeutic with the potential to recharge failing mitochondria. Our discussion traverses the innovative path Clene has charted, from the drug's conception to the exciting clinical trial results that highlight its capacity to enhance neurological functions and offer new hope to individuals grappling with ALS and multiple sclerosis.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Kapitler
1. Episode 57: Rob Etherington- CEO and President at Clene Nanomedicine (00:00:00)
2. Innovative Nanotherapeutic Approach for Neurodegenerative Diseases (00:00:06)
3. Advances in Neurodegenerative Disease Treatment (00:09:52)
4. Guest on Vile Podcast Expresses Gratitude (00:19:29)
62 episoder
Del
